A recent publication recommended approaches for the general management of breast cancer during the COVID-19 crisis and proposed the use of endocrine treatment and delay of surgery until after COVID-19 for T1N0ER+ HER2− breast cancer and considering this for T2 or N1 ER+ HER2− disease1. This evidence concerns the gene ESR1 and breast cancer.